tostran 20 mg/g gel
paranova danmark a/s - testosteron - gel - 20 mg/g
tostran 20 mg/g gel
2care4 aps - testosteron - gel - 20 mg/g
testogel 50 mg/dosis transdermal gel
orifarm a/s - testosteron - transdermal gel - 50 mg/dosis
testogel 50 mg/dosis transdermal gel
laboratoires besins int. s.a.s. - testosteron - transdermal gel - 50 mg/dosis
xtandi
astellas pharma europe b.v. - enzalutamide - prostatiske neoplasmer - endokrine terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
testavan 20 mg/g transdermal gel
orifarm a/s - testosteron - transdermal gel - 20 mg/g
testavan 20 mg/g transdermal gel
epione medicine aps - testosteron - transdermal gel - 20 mg/g
testogel 16,2 mg/g transdermal gel
2care4 aps - testosteron - transdermal gel - 16,2 mg/g
tostran 20 mg/g gel
abacus medicine a/s - testosteron - gel - 20 mg/g
testogel 25 mg/dosis transdermal gel
laboratoires besins int. s.a.s. - testosteronenantat - transdermal gel - 25 mg/dosis